Budigalimab, Placebo for Budigalimab (ABBV-181) - 0.9% Sodium Chloride or DILUENT, ABBV-382, Placebo for ABBV-382 Solution for Infusion
M19-965
Phase 2 small_molecule active
Quick answer
Budigalimab, Placebo for Budigalimab (ABBV-181) - 0.9% Sodium Chloride or DILUENT, ABBV-382, Placebo for ABBV-382 Solution for Infusion for HIV infection is a Phase 2 program (small_molecule) at AbbVie Deutschland GmbH & Co. KG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AbbVie Deutschland GmbH & Co. KG
- Indication
- HIV infection
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active